A higher forecast puts CareDx's 2026 revenue at $520M–$530M
CareDx reported Q3 2026 revenue of $139M, up 39% YoY, driven by Testing Services growth. The company raised its 2026 revenue guidance to $520M–$530M, acquired Naveris, and advanced pipeline programs. GAAP net income was $2M, up from $19M in Q3 2025. Adjusted EBITDA reached $15M, up from $30M YoY.
How this was made
The 30-second read
Why it matters
The raised guidance signals stronger demand for testing services and may improve the company's growth narrative, influencing investor sentiment.
Market read
First‑time guidance update for a mid‑cap biotech; likely to affect CDX price and sector peers.
What to watch
Execution risk on upcoming product launches and integration of recent acquisitions could temper expectations.
Background
CareDx, a precision‑medicine diagnostics company, issued a press release updating its 2026 revenue outlook and reporting recent acquisition and product progress.
Market effects
Higher guidance may boost sentiment for the precision‑medicine diagnostics sector.
U.S. biotech and healthcare stocks could see modest gains.
Limited to investors focused on U.S. listed biotech firms.
Counterpoint
If the guidance already priced in, the lift may be already reflected, limiting upside.
Key entities
- companyCareDx, Inc.
U.S. listed diagnostics firm (ticker CDX) providing transplant and oncology testing services.
